Page 10 - Pharma Intelligence Center News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Summary "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Diffuse Large B-cell Lymphoma (DLBCL) - Competitive Landscape in 2021" - https://www.reportlinker.com/p06035016/?utm_source=GNW CD-19 and CD-20 inhibitors are a major focus of drug developers.There are 387 drugs in the pipeline, 95x% 0f which are in early-...

Summary "Psoriasis - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.New York, March 12, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Psoriasis - Competitive Landscape in 2020" - https://www.reportlinker.com/p06035014/?utm_source=GNW Interleukin and tumor necrosis factor inhibitors are the major focus of drug developers.There are 350 drugs in the pipeline, 89% 0f which are in early-stage.Big pharma dominates R&...

This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website. Manage your cookiesI agree Cookie Settings Cookie Settings This website uses cookies to improve your experience whil...

Takeda continues collaboration run to bolster global immuno-oncology footprint, says GlobalData   The need to develop novel innovative cancer drugs at affordable prices is forcing large pharmaceutical firms to collaborate with biotech companies and academic institutions. Japan-based Takeda Pharmaceuticals too is focusing on strategic collaborations to bolster its global immuno-oncology (IO) footprint, says GlobalData, a leading data and analytics company.    In January 2021, Takeda entered a broad strategic collaboration with KSQ Therapeutics to research, develop and commercialize novel im...